JSbalaban

American Oriental Bioengineering Keeps Growing Despite Bad Moves

I wouldn't touch AOB due to their poor business decisions. The only thing that saves them is China's still relatively robust economy. AOB may have 82M in profit in Q4, but shareholders wont see much of that due to AOB's continued diluitive deals. Want a good pharma that grows as organically as possible and is a real cash cow for their size? Take a look at CSKI. For me, that's the one to own CSKI will double before AOB gives you 50%.

JBB